Company overview
ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd., founded in June 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early-stage biopharmaceutical company dedicated to development and commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells.
News Center
-
06-212022Phase I clinical trial of IMM2902 completed the first patient enrollment and dosing in the United States.On June 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the compa......See details
-
06-162022IMM2902 Invention Patent was Authorized by the US Patent OfficeOn June 16, 2022, Immuneonco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced th......See details
-
06-152022ImmuneOnco’s IMM27M，an ADCC-enhanced CTLA-4 antibody completed the first patient enrollment and dosingOn June 15, 2022, Immuneonco Biopharmaceuticals(Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced tha......See details